Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5983
    +0.0008 (+0.13%)
     
  • NZD/EUR

    0.5538
    +0.0005 (+0.09%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • NZD/JPY

    90.4640
    +0.0710 (+0.08%)
     

Global Pediatric Drugs and Vaccines Market to Reach $156.7 Billion by 2030

ReportLinker
ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pediatric Drugs and Vaccines Industry" - https://www.reportlinker.com/p06051298/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Pediatric Drugs and Vaccines Market to Reach $156.7 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Pediatric Drugs and Vaccines estimated at US$97.7 Billion in the year 2022, is projected to reach a revised size of US$156.7 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2022-2030. Conjugate, one of the segments analyzed in the report, is projected to record a 7.2% CAGR and reach US$52 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Live Attenuated segment is readjusted to a revised 6.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $26.6 Billion, While China is Forecast to Grow at 10.1% CAGR

The Pediatric Drugs and Vaccines market in the U.S. is estimated at US$26.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$35.4 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$21.4 Billion by the year 2030.

Select Competitors (Total 76 Featured)
- Abbott Laboratories
- Allergan Inc.
- Amgen Inc.
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Genentech Inc.
- GlaxoSmithKline Plc
- Janssen Biologics B.V
- Merck & Co. Inc.
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi
- Shionogi Inc.
- Shire Pharmaceuticals Group Plc


Read the full report: https://www.reportlinker.com/p06051298/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Pediatrics: A Highly Underserved and Undervalued Group
Recent Market Activity
Pediatric Drugs Market - An Abode of Opportunities
The United States: Largest Market for Pediatric Drugs and Vaccines
Developing Markets to Witness Faster Growth
Antibiotics: Largest Selling Drug Classes
Pediatric Vaccines Market - On High Growth Trajectory
Supply and Demand Dynamics of the Global Vaccine Market
UNICEF Addresses BCG Vaccine Supply Shortage
Access to Vaccines Index: Aiding Increased Access to Vaccines
Recent Advancements/Achievements in the Pediatric Vaccines Space
Pediatric Drugs and Vaccines - Global Key Competitors
Percentage Market Share in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS
Abbott Laboratories (USA)
Allergan, Inc. (USA)
Amgen, Inc. (USA)
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (USA)
GlaxoSmithKline plc. (UK)
Janssen Biologics B.V. (USA)
Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen
Pharmaceutical Company)
Merck & Co., Inc. (USA)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (USA)
Sanofi S.A (France)
Shionogi Inc. (USA)
Shire Pharmaceuticals Group Plc. (UK)

3. MARKET TRENDS & DRIVERS
Pediatric Exclusivity Drives Manufacturers? Interest
Pediatric Exclusitivity Granted to Branded Drugs
New Product Approvals and Pipeline - A Key Growth Propeller
Recent Pediatric Drug Approvals: 2015-2017
Pediatric Drug Approvals: 2011-2014
Phase III Completed Pediatric Drugs: 2015-2017 (As of July 2017)
Ongoing Phase III Pediatric Drugs Clinical Trials: 2015-2017:
(As of July 2017)
Potential for Pediatric Drugs Against Obesity-related Conditions
List of Pediatric Drugs for Congestive Heart Failure Treatment
Recent Findings to Help Save Children?s Lives
Challenges of Pediatric Drug Development: Formulation Problems
and Ethical Constraints of Clinical Trials
Financial Enticement for Drug Makers to Conduct Dedicated
Pediatric Trials
Modeling & Simulation - A Powerful Tool for Pediatric Clinical
Study Sponsors
Pharmacometrics Approaches Gain Traction Among US and EU
Researchers
Challenges Associated with Adoption of Pharmacometric Approach
Guidelines for Conducting Ethically Correct Clinical Trials
Pediatric Drug Market - Is Off-label Prescription Justified?
Indian Drug Manufacturers Develop Pneumococcal Conjugate Vaccine
High Vaccination Costs: A Major Hindrance for Pneumonia
Vaccination
Vaccine Refusal by Parents - A Growing Trend in the US Market
Orphan Drugs for Pediatric Use Gain Popularity
List of FDA Approved Orphan Drugs: 2015-2016
List of FDA Designated Orphan Drugs: 2015-2017
Pediatric Review Vouchers Foster Innovation in Rare Pediatric
Drugs
Need for Higher Focus on Fixed-Dose Combination for Pediatric
HIV Infections
Approved Pediatric Antiretroviral Drugs for HIV Treatment
Highly Fragmented Growth Hormone Market

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Pediatric Drugs and Vaccines
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 3: World 18-Year Perspective for Pediatric Drugs and
Vaccines by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Conjugate by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Conjugate by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 6: World 18-Year Perspective for Conjugate by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for Live
Attenuated by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Live Attenuated by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 9: World 18-Year Perspective for Live Attenuated by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Inactivated by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Inactivated by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 12: World 18-Year Perspective for Inactivated by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
Subunit by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Subunit by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 15: World 18-Year Perspective for Subunit by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Toxoid by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Toxoid by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 18: World 18-Year Perspective for Toxoid by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for
Other Technologies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Other Technologies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 21: World 18-Year Perspective for Other Technologies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Vaccines by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 24: World 18-Year Perspective for Vaccines by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Drugs by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 26: World Historic Review for Drugs by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 27: World 18-Year Perspective for Drugs by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2023 & 2030

Table 28: World Pediatric Drugs and Vaccines Market Analysis of
Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

UNITED STATES
Pediatric Drugs and Vaccines Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2023
(E)
Table 29: USA Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 30: USA Historic Review for Pediatric Drugs and Vaccines
by Technology - Conjugate, Live Attenuated, Inactivated,
Subunit, Toxoid and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2021 and % CAGR

Table 31: USA 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 32: USA Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 33: USA Historic Review for Pediatric Drugs and Vaccines
by Product Type - Vaccines and Drugs Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2021 and % CAGR

Table 34: USA 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

CANADA
Table 35: Canada Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 36: Canada Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 37: Canada 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 38: Canada Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 39: Canada Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 40: Canada 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

JAPAN
Pediatric Drugs and Vaccines Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 41: Japan Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 42: Japan Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 43: Japan 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 44: Japan Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 45: Japan Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 46: Japan 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

CHINA
Pediatric Drugs and Vaccines Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2023 (E)
Table 47: China Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 48: China Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 49: China 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 50: China Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 51: China Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 52: China 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

EUROPE
Pediatric Drugs and Vaccines Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 53: Europe Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 54: Europe Historic Review for Pediatric Drugs and
Vaccines by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR

Table 55: Europe 18-Year Perspective for Pediatric Drugs and
Vaccines by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2023 & 2030

Table 56: Europe Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 57: Europe Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 58: Europe 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 59: Europe Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 60: Europe Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 61: Europe 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

FRANCE
Pediatric Drugs and Vaccines Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2023 (E)
Table 62: France Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 63: France Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 64: France 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 65: France Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 66: France Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 67: France 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

GERMANY
Pediatric Drugs and Vaccines Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 68: Germany Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 69: Germany Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 70: Germany 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 71: Germany Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 72: Germany Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 73: Germany 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

ITALY
Table 74: Italy Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 75: Italy Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 76: Italy 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 77: Italy Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 78: Italy Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 79: Italy 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

UNITED KINGDOM
Pediatric Drugs and Vaccines Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for 2023
(E)
Table 80: UK Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 81: UK Historic Review for Pediatric Drugs and Vaccines
by Technology - Conjugate, Live Attenuated, Inactivated,
Subunit, Toxoid and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2021 and % CAGR

Table 82: UK 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 83: UK Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 84: UK Historic Review for Pediatric Drugs and Vaccines
by Product Type - Vaccines and Drugs Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2021 and % CAGR

Table 85: UK 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

SPAIN
Table 86: Spain Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 87: Spain Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 88: Spain 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 89: Spain Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 90: Spain Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 91: Spain 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

RUSSIA
Table 92: Russia Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 93: Russia Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 94: Russia 18-Year Perspective for Pediatric Drugs and
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid
and Other Technologies for the Years 2012, 2023 & 2030

Table 95: Russia Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 96: Russia Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 97: Russia 18-Year Perspective for Pediatric Drugs and
Vaccines by Product Type - Percentage Breakdown of Value Sales
for Vaccines and Drugs for the Years 2012, 2023 & 2030

REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Pediatric Drugs and Vaccines by Technology - Conjugate,
Live Attenuated, Inactivated, Subunit, Toxoid and Other
Technologies - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 99: Rest of Europe Historic Review for Pediatric Drugs
and Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 100: Rest of Europe 18-Year Perspective for Pediatric
Drugs and Vaccines by Technology - Percentage Breakdown of
Value Sales for Conjugate, Live Attenuated, Inactivated,
Subunit, Toxoid and Other Technologies for the Years 2012, 2023 &
2030

Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Pediatric Drugs and Vaccines by Product Type -
Vaccines and Drugs - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 102: Rest of Europe Historic Review for Pediatric Drugs
and Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 103: Rest of Europe 18-Year Perspective for Pediatric
Drugs and Vaccines by Product Type - Percentage Breakdown of
Value Sales for Vaccines and Drugs for the Years 2012, 2023 &
2030

ASIA-PACIFIC
Pediatric Drugs and Vaccines Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Pediatric Drugs and Vaccines by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 105: Asia-Pacific Historic Review for Pediatric Drugs and
Vaccines by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2021 and %
CAGR

Table 106: Asia-Pacific 18-Year Perspective for Pediatric Drugs
and Vaccines by Geographic Region - Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2023 & 2030

Table 107: Asia-Pacific Recent Past, Current & Future Analysis
for Pediatric Drugs and Vaccines by Technology - Conjugate,
Live Attenuated, Inactivated, Subunit, Toxoid and Other
Technologies - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 108: Asia-Pacific Historic Review for Pediatric Drugs and
Vaccines by Technology - Conjugate, Live Attenuated,
Inactivated, Subunit, Toxoid and Other Technologies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 109: Asia-Pacific 18-Year Perspective for Pediatric Drugs
and Vaccines by Technology - Percentage Breakdown of Value
Sales for Conjugate, Live Attenuated, Inactivated, Subunit,
Toxoid and Other Technologies for the Years 2012, 2023 & 2030

Table 110: Asia-Pacific Recent Past, Current & Future Analysis
for Pediatric Drugs and Vaccines by Product Type - Vaccines and
Drugs - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 111: Asia-Pacific Historic Review for Pediatric Drugs and
Vaccines by Product Type - Vaccines and Drugs Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR

Table 112: Asia-Pacific 18-Year Perspective for Pediatric Drugs
and Vaccines by Product Type - Percentage Breakdown of Value
Sales for Vaccines and Drugs for the Years 2012, 2023 & 2030

AUSTRALIA
Pediatric Drugs and Vaccines Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Australia for 2023 (E)
Table 113: Australia Recent Past, Current & Future Analysis for
Pediatric Drugs and Vaccines by Technology - Conjugate, Live
Attenuated, Inactivated, Subunit, Toxoid and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 114: Australia Historic Review for Pediatric Drugs and

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06051298/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001